Insulet Co. (NASDAQ:PODD) Director David A. Lemoine sold 8,752 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $106.92, for a total value of $935,763.84. Following the completion of the transaction, the director now owns 9,148 shares in the company, valued at approximately $978,104.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
David A. Lemoine also recently made the following trade(s):
- On Friday, March 1st, David A. Lemoine sold 561 shares of Insulet stock. The shares were sold at an average price of $94.29, for a total value of $52,896.69.
PODD stock traded down $2.30 during midday trading on Friday, reaching $103.90. 393,939 shares of the company’s stock traded hands, compared to its average volume of 725,968. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.71. Insulet Co. has a 52 week low of $70.80 and a 52 week high of $108.90. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of 2,078.00 and a beta of 1.50.
Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.05. The business had revenue of $159.56 million for the quarter, compared to analysts’ expectations of $154.66 million. Insulet had a net margin of 2.37% and a return on equity of 7.01%. The business’s revenue for the quarter was up 29.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.11) EPS. Equities research analysts anticipate that Insulet Co. will post 0.26 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in PODD. FMR LLC grew its position in Insulet by 0.3% in the first quarter. FMR LLC now owns 8,821,151 shares of the medical instruments supplier’s stock worth $838,802,000 after acquiring an additional 30,262 shares in the last quarter. Jane Street Group LLC purchased a new position in Insulet in the first quarter worth $292,000. Zebra Capital Management LLC purchased a new position in Insulet in the first quarter worth $202,000. Schonfeld Strategic Advisors LLC purchased a new position in Insulet in the first quarter worth $397,000. Finally, M&T Bank Corp grew its position in Insulet by 22.3% in the first quarter. M&T Bank Corp now owns 7,662 shares of the medical instruments supplier’s stock worth $729,000 after acquiring an additional 1,398 shares in the last quarter.
PODD has been the topic of several research analyst reports. BidaskClub upgraded Insulet from a “hold” rating to a “buy” rating in a research note on Wednesday, February 13th. Oppenheimer set a $100.00 price objective on Insulet and gave the company a “hold” rating in a research note on Tuesday, February 26th. Northland Securities reiterated a “buy” rating and issued a $100.00 price objective on shares of Insulet in a research note on Tuesday, February 26th. Canaccord Genuity upped their price objective on Insulet from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, February 19th. Finally, BTIG Research upgraded Insulet from a “neutral” rating to a “buy” rating and set a $115.00 price objective on the stock in a research note on Monday, May 6th. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $105.18.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Read More: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.